The Pennine Acute Hospitals
NHS Trust Formulary
 
back
9 Nutrition and blood
09-01-03 Erythropoietin

MHRA Drug Safety Update 2007

Overcorrection of haemoglobin concentration in patients with chronic kidney disease may increase the risk of death and serious cardiovascular events. In patients with cancer, clinical trial data show an unexplained excess mortality and increased risk of tumour progression with erythropoietin treatment, and overcorrection of haemoglobin concentration may increase the risk of thrombosis and related complications.

• Patients should only be treated when symptoms of anaemia are present

• The haemoglobin concentration should be maintained within the range 10-12g/100ml (avoid concentrations higher than 12g/100ml). The haemaglobin concentration should not be increased beyond that which provides adequate control of symptoms of anaemia.

• Treatment of symptomatic anaemia with erythropoeitins in patients with cancer is only licensed for patients receiving chemotherapy.

• The decision to use erythropoietin should be based on an assessment of the benefits and risks for individual patients; blood transfusion may be the preferred treatment for anaemia associated with cancer chemotherapy.

 

There have been very rare reports of pure red cell aplasia in patients treated with epoetin alfa. These patients should not be switched to another form of erythropoietin.


Darbepoetin Alfa Aranesp®
First Choice
Injection

Red View adult BNF  View SPC online  View childrens BNF
Epoetin alfa Eprex®
First Choice
Injection

Red View adult BNF  View SPC online  View childrens BNF
Epoetin beta NeoRecormon®
Formulary
Injection

Red View adult BNF  View SPC online  View childrens BNF
Epoetin Theta Eporatio®
Non Formulary

View adult BNF  View SPC online  View childrens BNF
Methoxy Polyethylene Glycol-Epoetin Beta Mircera®
Non Formulary

View adult BNF  View SPC online  View childrens BNF